Neurological complications associated with anti–programmed death 1 (PD-1) antibodies
JC Kao, B Liao, SN Markovic, CJ Klein… - JAMA …, 2017 - jamanetwork.com
Importance Neurological complications are an increasingly recognized consequence of the
use of anti–programmed death 1 (PD-1) antibodies in the treatment of solid-organ tumors,
with an estimated frequency of 4.2%. To date, the clinical spectrum and optimum treatment
approach are not established. Objective To investigate the frequency, clinical spectrum, and
optimum treatment approach to neurological complications associated with anti–PD-1
therapy. Design, Setting, and Participants This single-center, retrospective cohort study was …
use of anti–programmed death 1 (PD-1) antibodies in the treatment of solid-organ tumors,
with an estimated frequency of 4.2%. To date, the clinical spectrum and optimum treatment
approach are not established. Objective To investigate the frequency, clinical spectrum, and
optimum treatment approach to neurological complications associated with anti–PD-1
therapy. Design, Setting, and Participants This single-center, retrospective cohort study was …
